Muenke Syndrome
Isolated Craniosynostosis; Non-Syndromic Craniosynostosis; Coronal Craniosynostosis
It is the responsibility of the ordering physician to ensure that informed consent has been obtained from the patient/legal guardian before ordering genetic testing. Please review the following Pre-Test Counselling Information with your patient before requesting any of our genetic tests.
Clinical Features
The phenotype of Muenke syndrome varies considerably. Clinical features may include cranial suture synostosis, ocular hypertelorism, ptosis or proptosis, midface hypoplasia, temporal bossing, high-arched palate, strabismus, hearing loss, developmental delay, intellectual disability; carpal bone and/or tarsal bone fusions brachydactyly, broad toes, broad thumbs, and clinodactyly.
Genetics
Muenke syndrome is inherited in an autosomal dominant manner, but shows reduced penetrance. All individuals are heterozygous for the FGFR3 mutation c.749C>G (p.Pro250Arg).
Indications for Testing
- Confirmation of diagnosis:
- In individuals with clinical features suggestive of Muenke syndrome (non-syndromic craniosynostosis).
- Carrier testing:
- Although this is an autosomal dominant condition, carrier testing may be relevant to identify non-penetrant mutation carriers.
- Prenatal testing (technically feasible but not routinely performed – contact MGL to discuss):
- In pregnancies of a couple in which one parent has Muenke syndrome.
Description of this Assay
Bidirectional Sanger sequencing across the c.749C>G (p.Pro250Arg) FGFR3 mutation.
Reference Sequence
NM_000142.4 The ‘A’ within the initiation codon, ATG, is designated as nucleotide number 1.
Sensitivity and Limitations
The mutation detected by this assay accounts for greater than 99% of individuals with Muenke syndrome. In individuals with apparently isolated unilateral coronal craniosynostosis, the detection rate for this mutation has been reported to be approximately 4 – 12%, while in individuals with apparently isolated bilateral coronal craniosynostosis, the detection rate of this mutation is approximately 30 – 40%. Other forms of craniosynostosis, caused by other mutations in FGFR3 or by mutations in other genes, are not detected by this assay.
Turnaround Time
Routine
6 weeks
Specimen Requirements
Blood: 4 mL EDTA is optimal (Minimum: 1 mL EDTA)
DNA: 100 μL at 200 ng/μL is optimal (Minimum: 30 μL at 200 ng/μL)
Label each sample with three patient identifiers; preferably patient name, PHN, and date of birth and ship to the address below. Samples should be shipped at room temperature with a completed MGL Requisition to arrive Monday to Friday (not on Canadian statutory holidays).
Prenatal Specimens
Prenatal testing REQUIRES LABORATORY CONSULTATION PRIOR TO THE PROCEDURE and can only be ordered by a Medical Geneticist. Contact the laboratory at 604-875-2852 and choose the appropriate option for the Molecular Geneticist on service.
Chorionic Villi: 20 mg.
Direct Amniotic fluid: 25 mL collected in two separate tubes of equal volume.
Cultured Amniocytes: Two (2) 100% confluent T-25 flasks.
DNA extracted from prenatal specimens: 100 μL at 200 ng/μL is optimal (Minimum: 30 μL at 200 ng/μL)
Label each sample with three patient identifiers; preferably patient name, PHN, and date of birth. Ship samples by overnight courier with a completed MGL Requisition to arrive Monday to Friday (not on Canadian statutory holidays) as follows:
- Villi – on wet ice or in media at room temperature
- Amniocytes, Amniotic fluid, DNA – at room temperature
Shipping Address
Specimen Receiving Room 2J20
Children’s & Women’s Health Centre of British Columbia – Laboratory
4500 Oak Street, Vancouver, BC, V6H 3N1
Test Price and Billing
Testing is only available to residents of Canada, except in very specific circumstances where testing is urgent or emergent. Payment is not required when requests are made for individuals who are insured by Health Insurance BC (administered through the BC Medical Services Plan (MSP)) AND eligible for testing according to the test utilization guidelines / policy. If the individual undergoing testing is not insured by these providers or does not meet utilization guidelines or policy, please complete a billing form; testing will only commence after receipt of billing informationTest prices can be found here.
Cautions
Molecular genetic testing is limited by the current understanding of the genome and the genetics of a particular disease, as well as by the method of detection used.
Rare single nucleotide variants or polymorphisms could lead to false-negative or false-positive results. If results obtained do not match the clinical findings, consult the on-service Molecular Geneticist.
A previous bone marrow transplant from an allogenic donor will result in molecular data that reflects the donor genotype rather than the recipient (patient) genotype. Consult the on-service Molecular Geneticist for approach to testing in such individuals.
Transfusions performed with packed red blood cells will generally not affect the outcome of molecular genetic testing. However, if there is no clinical urgency, the cautious approach is to wait one week post packed red cell transfusion before collecting a sample for genetic testing. Consult the on-service Molecular Geneticist as needed.
Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Errors in our interpretation of results may occur if information given is inaccurate or incomplete.